TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03708536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab (7.5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 2000mg/m2/d is administered orally on days 1 to 14 of a 21-day cycle.
Study: NCT03622229

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Histologic evaluation
Description: Samples collected by EUS-FNB without ROSE will be processed as histologic samples

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Histologic evaluation
Description: Samples collected by EUS-FNB without ROSE will be processed as histologic samples
Study: NCT03245333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Growth Hormone Injection
Description: Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.
Study: NCT02105012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD MDI 40 µg
Description: Budesonide Inhalation Aerosol administered as 2 inhalations BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo MDI administered as 2 inhalations BID
Study: NCT01993680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide
Description: Drug doses during the trial:~Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludrocortisone
Description: drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days
Study: NCT03844035

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Periimplant crevicular fluid (PICF) collection
Description: Prior to PICF sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, New York, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed PICF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80⁰C. The readings were converted to an actual volume (µl) by reference to the standard curve.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Periimplant crevicular fluid (PICF) collection
Description: Prior to PICF sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, New York, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed PICF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80⁰C. The readings were converted to an actual volume (µl) by reference to the standard curve.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Periimplant crevicular fluid (PICF) collection
Description: Prior to PICF sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, New York, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed PICF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80⁰C. The readings were converted to an actual volume (µl) by reference to the standard curve.
Study: NCT04867629

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rapeseed oil
Description: 20mL of rapeseed oil to be consumed daily in replacement to habitual oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sunflower oil
Description: 20mL of sunflower oil to be consumed daily in replacement to habitual oil
Study: NCT02458027

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hemp Shake
Description: Hemp Protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hemp
Description: Hemp Protein Shake

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soybean Shake
Description: Soybean Protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soybean
Description: Soybean Protein Shake

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non-Protein Shake
Study: NCT05815264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal vaccine polyvalent
Description: This vaccine（0.5ml） is produced by Merck Sharp \& Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal vaccine polyvalent
Description: This vaccine（0.5ml） is produced by Merck Sharp \& Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal vaccine polyvalent
Description: This vaccine（0.5ml） is produced by Merck Sharp \& Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.
Study: NCT02118415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hsp70-peptide TKD/IL-2 activated, autologous NK cells
Description: Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)
Study: NCT02957903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
Study: NCT01903720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone implant
Description: OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
Study: NCT03470883

Intervention type: OTHER
Intervention: Evaluation of the long-term complete remission rate (> 12 months)
Description: Evaluation of the long-term complete remission rate (\> 12 months)
Study: NCT02006615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional near infrared spectroscopy
Description: Using high-sensitivity infrared to detect the active brain areas

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: To modulate brain cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: To modulate brain cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: To modulate brain cortex
Study: NCT01259531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
Study: NCT04080531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: Given IM
Study: NCT04619849

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EMG
Description: Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Palmaris Longus Test
Description: Schaffer test will be done to understand the presence of palmaris longus. 4 different tests will be done to prove its absence.
Study: NCT04205916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Drugs to be administer during cataract surgery to experimental group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care surgery
Description: Standard method used for surgery and the use of post operative drops
Study: NCT00309946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study: NCT02118831

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample Collection
Description: Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample Collection
Description: Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample Collection
Description: Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: an intravitreal injection of Aflibercept administered three times on a monthly basis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: an intravitreal injection of Bevacizumab administered three times on a monthly basis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: an intravitreal injection of Ranibizumab administered three times on a monthly basis.
Study: NCT04491110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be done by using mobile telephones.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: simulation with therapeutic education
Description: Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through mobile phones.
Study: NCT02096887

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Education
Description: Patient Education using the following two instruments:~1. Framingham Risk Score calculator:~2. Know your numbers patient booklet
Study: NCT02934217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of Cyclosporin
Description: one single intravenous bolus injection of 2.5 mg/Kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single intravenous bolus injection of Placebo

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiography
Description: 3 years after AMI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: 3 years after AMI
Study: NCT01366274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protective manual hyperinflation
Description: Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 8mls/kg and positive end expiratory pressure in the circuit appropriate to baseline levels

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual method of MHI
Description: Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 12mls/kg and no positive end expiratory pressure in the circuit
Study: NCT03232892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2mg, once daily, PO, 28-day cycles
Study: NCT03851952

Intervention type: DEVICE
Group type: OTHER
Intervention: Optilume Drug Coated Balloon
Description: The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
Study: NCT03678857

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants will resistance train their left arm and left leg one day and their right arm and right leg the next day. Participants will supplement with creatine BEFORE one of the training days (randomized to either left or right side) and on the opposite training day (opposite side of the body to the previous training day) supplement with creatine AFTER training. Having the same person in both conditions will control for genetics, habitual diet, other daily activities, and so on, that may have confounded previous research. Muscle mass and strength changes will be measured in each limb prior to and following 8 weeks of training to determine whether creatine timing influenced muscle growth.~Research Question: To determine whether creatine supplementation timing (i.e., before versus after training) effects 8 weeks of resistance training adaptations (i.e., muscle growth and strength changes).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants will resistance train their left arm and left leg one day and their right arm and right leg the next day. Participants will supplement with creatine BEFORE one of the training days (randomized to either left or right side) and on the opposite training day (opposite side of the body to the previous training day) supplement with creatine AFTER training. Having the same person in both conditions will control for genetics, habitual diet, other daily activities, and so on, that may have confounded previous research. Muscle mass and strength changes will be measured in each limb prior to and following 8 weeks of training to determine whether creatine timing influenced muscle growth.~Research Question: To determine whether creatine supplementation timing (i.e., before versus after training) effects 8 weeks of resistance training adaptations (i.e., muscle growth and strength changes).
Study: NCT01546987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: LHRH agonists are administered with a variety of techniques. The manufacturer's instructions should be followed. Begins within 6 weeks after registration (if not started prior) at same time as anti-androgen and TAK-700 (if applicable).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: LHRH agonists are administered with a variety of techniques. The manufacturer's instructions should be followed. Begins within 6 weeks after registration (if not started prior) at same time as anti-androgen and TAK-700 (if applicable).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-androgen
Description: Starts at same time as GnRH agonist, ends at end of radiation therapy. Either flutamide (orally 250 mg three times a day) or bicalutamide (orally 50 mg once a day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-androgen
Description: Starts at same time as GnRH agonist, ends at end of radiation therapy. Either flutamide (orally 250 mg three times a day) or bicalutamide (orally 50 mg once a day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700
Description: 300 mg twice daily (BID) (600 mg per day) orally, continuously for 2 years starting with ADT.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Starts 8-10 weeks after initiation of ADT. Initially 45 Gy (1.8 Gy / fraction) to prostate and pelvic lymph nodes delivered with 3DCRT/IMRT, then a boost using intensity-modulated radiation therapy (IMRT), low dose rate (LDR) brachytherapy, or high dose rate (HDR) brachytherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Starts 8-10 weeks after initiation of ADT. Initially 45 Gy (1.8 Gy / fraction) to prostate and pelvic lymph nodes delivered with 3DCRT/IMRT, then a boost using intensity-modulated radiation therapy (IMRT), low dose rate (LDR) brachytherapy, or high dose rate (HDR) brachytherapy.
Study: NCT03111108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBR/GZR (50 mg/100 mg) FDC
Description: One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBR/GZR (50 mg/100 mg) FDC
Description: One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
Study: NCT03245333

Intervention type: DRUG
Group type: OTHER
Intervention: Recombinant Human Growth Hormone Injection
Description: Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Growth Hormone Injection
Description: Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Recombinant Human Growth Hormone Injection
Description: Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Growth Hormone Injection
Description: Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.

Intervention type: DRUG
Group type: OTHER
Intervention: Recombinant Human Growth Hormone Injection
Description: Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Growth Hormone Injection
Description: Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.

Intervention type: DRUG
Group type: OTHER
Intervention: Recombinant Human Growth Hormone Injection
Description: Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.
Study: NCT00397735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: amniocentesis
Description: Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: amniocentesis
Description: Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine or placebo
Description: Only women with amniocentesis results consistent with infection/inflammation will be randomized

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine or placebo
Description: Only women with amniocentesis results consistent with infection/inflammation will be randomized
Study: NCT02579226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2811
Description: The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2811
Description: The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
Study: NCT01070745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
Study: NCT00936351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses. This intervention has been adapted from mindfulness based stress reduction treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group (control)
Description: A support group during which participants can discuss with each other any issues, problems, or successes at work will be conducted as the control portion.